9
Mar
Biosimilars are billed under Medicare Part B using unique HCPCS codes and a 106% reimbursement formula tied to the reference product’s price. This structure unintentionally discourages adoption, as providers earn more from higher-priced drugs. Learn how billing works, why U.S. adoption lags behind Europe, and what reforms are being considered.
More